echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > In the next 5 years, there will be three major trends in Chinese pharmaceutical innovation

    In the next 5 years, there will be three major trends in Chinese pharmaceutical innovation

    • Last Update: 2020-11-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    In recent years, with the deepening of China's drug regulatory policy reform, the idea of encouraging clinical value-oriented drug innovation has become more and more clear.
    under the guidance of the top-level policy, China's investment in pharmaceutical innovation continues to grow, and the number of innovative drugs in China has also begun to increase.
    data show that the number of clinical declarations of innovative drugs in China showed an overall growth trend in 2008-2018, with 303 applications for clinical trials of innovative drugs in 2017, up 48.5% Year-on-Year, and a decrease in 2018, but a more than sixfold increase in chemical IND compared to 2008.
    next five years, China's pharmaceutical innovation will have three major trends (photo source: pharmaceutical network) to this, industry insiders believe that China's innovative drug development has begun.
    but it is important to note that behind the innovation and change, the development logic and rules of the pharmaceutical industry are quietly changing.
    this can actually be seen from the current development layout of many pharmaceutical companies.
    For the recent new chairman of People's Fu Pharmaceuticals Li Jie publicly said that the future development of his company, on the one hand, in accordance with the plan to speed up the divestiture of non-core assets, continue to optimize the business structure, further achieve business focus;
    And Watson Pharmaceuticals said on the interactive platform some time ago, the company has been in the innovative drug sector action, such as the introduction of the first scientific officer, the establishment of innovative pharmaceutical business unit, the construction of innovative pharmaceutical laboratories, the creation of innovative pharmaceutical talent team, etc., has been partially completed or is in the process of advancing, the follow-up specific projects will be carried out in an orderly manner as planned.
    Fan Pharmaceuticals has also decided to adjust its organizational structure, according to its previously released 2019 annual report shows that it will combine the "integration, innovation and internationalization" of the medium- and long-term development strategy, the establishment of Yifan Pharmaceutical (small molecules) business unit, began to lay out the first imitation after the creation of small molecules "research and marketing" integration.
    above, the rules of the game in the pharmaceutical industry have changed dramatically, from a focus on marketing in the past to an accelerated transition to innovation.
    industry expects that in the trend of innovation and development, the future of the traditional pharmaceutical companies will face a very big challenge, and the era of new start-ups has arrived.
    the future of China's innovative pharmaceutical industry into a rapid growth, the pharmaceutical industry will be what specific trends? Some industry experts predict that its main three major trends.
    , in the next 5 years, the domestic innovation ecology "policy -research and development-payment" will have a prototype, and under the continuous upgrading of the pharmaceutical industry, it will become the world's second largest innovation drug research and development base.
    , the past five years, the main investment in large varieties of me-too products, in the next five years with FIC / BIC varieties of companies will also be very growth and scarcity, or will be born a billion U.S. dollars level of international varieties.
    , PD-1, mono-resistance, small-molecule targeted drug wave, ADC, dual resistance, RNAi, gene editing, mRNA and other innovative new technologies stags, Chinese enterprises are expected to make a major breakthrough in technological innovation, and the gap with the international frontier will be further narrowed.
    Overall, in the past, the competition between Chinese pharmaceutical companies mainly focused on the strength of sales capacity, but in the future, Chinese pharmaceutical companies will shift from the competition of sales ability to product development competition, more innovative drugs and adaptive drug companies will undoubtedly get more opportunities.
     
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.